LONDON, March 2 (Reuters) - Haleon (HLN.L), the world's biggest standalone consumer health business with brands such as Sensodyne toothpaste and Advil painkillers, reported its first full-year results on Thursday which analysts said were in line with expectations.
Analysts said on Thursday that Haleon has had a strong start to 2023, and its full-year revenue growth forecast of 4% to 6% was in line or just ahead of consensus estimates.
Rivals with consumer health operations, such as Bayer (BAYGn.DE) and Reckitt (RKT.L), have charged higher prices to partly offset broader falls in sales volumes.
"Our organic (full-year) revenue growth ... was well balanced between volume and price, with two thirds of the business gaining or holding share," McNamara said.
Haleon, which is made up of assets previously owned by GSK and Pfizer (PFE.N) reported organic revenue growth of 9% last year, just ahead of the 8-8.5% increase it predicted for 2022.